This document summarizes a study analyzing the flavor chemicals found in 30 electronic cigarette fluids from two disposable e-cigarette brands and refill bottles from local vape shops. The study found:
1) Total flavor chemical levels ranged from approximately 1-4% (10-40 mg/mL) in many liquids, while labeled nicotine levels ranged from 0.6-2.4% (6-24 mg/mL).
2) Many of the flavor chemicals identified were aldehydes, a class of compounds known to irritate respiratory tract tissue.
3) Vanillin and/or ethyl vanillin, potential respiratory irritants, were found in 17 of the liquids as one
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)UCT ICO
1) The document discusses potential scenarios for the population-level effects of electronic nicotine delivery systems (ENDS) such as e-cigarettes. It outlines both a best case scenario where ENDS help many smokers quit and a worst case scenario where ENDS increase smoking rates and normalize smoking behaviors.
2) The evidence to date suggests health risks from long-term nicotine exposure through ENDS use, as well as risks from other chemicals in e-liquids. Studies also show low real-world cessation rates for ENDS compared to other methods.
3) There are concerns about rapid uptake of ENDS use among youth and nonsmokers, as well as the tobacco industry's involvement in the ENDS
1. The document discusses the potential for e-cigarettes and other reduced risk nicotine products to significantly reduce smoking-related harm and death on a global scale. It outlines scenarios where low-risk nicotine products could drive down the number of smokers from over 1 billion currently to just 5% of the global adult population by 2050.
2. However, it notes that an over-regulated environment that reduces product appeal and diversity could limit the public health benefits by decreasing the number of smokers who switch to less harmful alternatives. The document argues for a balanced, evidence-based approach that recognizes both the massive potential gains and relatively minor risks of low-risk nicotine products.
3. In conclusion, it advocates that
This document provides information on vaping and tobacco harm reduction. It discusses how smoking kills over 96,000 people annually in the UK and notes that median smokers lose 10 years of life expectancy. It then examines smoking prevalence data in different areas and populations in the UK. The document discusses evidence that vaping is substantially less harmful than smoking and may help smokers quit. It notes concerns that restrictive policies could perpetuate smoking. The summary concludes by outlining a framework for risk-proportionate regulation of tobacco and nicotine products.
E-Cigarette Summit Speaker: Clive BatesLindsay Fox
Regulation: when less is more
Slides from Clive Bates' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
How e cigarettes should be regulated in uk ecig summitMatt Stan
This document summarizes a presentation on proposed changes to e-cigarette regulation in the UK and EU. It discusses the current state of e-cigarette use and harm reduction, NICE guidance supporting harm reduction approaches, and the ongoing revision of the EU Tobacco Products Directive to determine regulations for e-cigarettes. Key points addressed include evidence that cutting down smoking provides little health benefit on its own but may with nicotine replacement therapy, and NICE's recommendation that licensed nicotine products are less harmful than tobacco for harm reduction.
Tobacco harm reduction in the UK: e-cigarettes (EC) are making a differenceClive Bates
The document discusses the success of e-cigarettes in helping smokers quit in Leicester City, UK. It notes that success rates were up to 20% higher using e-cigarettes compared to nicotine replacement therapy alone. A stop smoking service in Leicester City began offering free e-cigarette starter kits in 2014 and has seen consistently high quit rates each year since. Common myths about potential health harms, nicotine addiction, e-cigarettes not reflecting smoker preferences, gateway effects, and lack of evidence are addressed. Key organizations in the UK support e-cigarettes as much safer than smoking and effective for harm reduction.
Vaping and tobacco: six things you need to know about harm reductionClive Bates
1. Smoking has not gone away
2. Technologies to obsolete cigarettes
3. Risks and risk (mis)perceptions
4. The public health mechanism and the pleasure principle
5. The youth vaping epidemic – a harder look
6. Policymaking and perverse consequences
This document summarizes a study analyzing the flavor chemicals found in 30 electronic cigarette fluids from two disposable e-cigarette brands and refill bottles from local vape shops. The study found:
1) Total flavor chemical levels ranged from approximately 1-4% (10-40 mg/mL) in many liquids, while labeled nicotine levels ranged from 0.6-2.4% (6-24 mg/mL).
2) Many of the flavor chemicals identified were aldehydes, a class of compounds known to irritate respiratory tract tissue.
3) Vanillin and/or ethyl vanillin, potential respiratory irritants, were found in 17 of the liquids as one
Visualising possible scenarios with ENDS (Electronic Nicotine Delivery Systems)UCT ICO
1) The document discusses potential scenarios for the population-level effects of electronic nicotine delivery systems (ENDS) such as e-cigarettes. It outlines both a best case scenario where ENDS help many smokers quit and a worst case scenario where ENDS increase smoking rates and normalize smoking behaviors.
2) The evidence to date suggests health risks from long-term nicotine exposure through ENDS use, as well as risks from other chemicals in e-liquids. Studies also show low real-world cessation rates for ENDS compared to other methods.
3) There are concerns about rapid uptake of ENDS use among youth and nonsmokers, as well as the tobacco industry's involvement in the ENDS
1. The document discusses the potential for e-cigarettes and other reduced risk nicotine products to significantly reduce smoking-related harm and death on a global scale. It outlines scenarios where low-risk nicotine products could drive down the number of smokers from over 1 billion currently to just 5% of the global adult population by 2050.
2. However, it notes that an over-regulated environment that reduces product appeal and diversity could limit the public health benefits by decreasing the number of smokers who switch to less harmful alternatives. The document argues for a balanced, evidence-based approach that recognizes both the massive potential gains and relatively minor risks of low-risk nicotine products.
3. In conclusion, it advocates that
This document provides information on vaping and tobacco harm reduction. It discusses how smoking kills over 96,000 people annually in the UK and notes that median smokers lose 10 years of life expectancy. It then examines smoking prevalence data in different areas and populations in the UK. The document discusses evidence that vaping is substantially less harmful than smoking and may help smokers quit. It notes concerns that restrictive policies could perpetuate smoking. The summary concludes by outlining a framework for risk-proportionate regulation of tobacco and nicotine products.
E-Cigarette Summit Speaker: Clive BatesLindsay Fox
Regulation: when less is more
Slides from Clive Bates' presentation at the E-Cigarette Summit, London November 12, 2013.
Full summary of the E-Cigarette Summit: http://ecigarettereviewed.com/e-cigarette-summit-london-summary
How e cigarettes should be regulated in uk ecig summitMatt Stan
This document summarizes a presentation on proposed changes to e-cigarette regulation in the UK and EU. It discusses the current state of e-cigarette use and harm reduction, NICE guidance supporting harm reduction approaches, and the ongoing revision of the EU Tobacco Products Directive to determine regulations for e-cigarettes. Key points addressed include evidence that cutting down smoking provides little health benefit on its own but may with nicotine replacement therapy, and NICE's recommendation that licensed nicotine products are less harmful than tobacco for harm reduction.
Tobacco harm reduction in the UK: e-cigarettes (EC) are making a differenceClive Bates
The document discusses the success of e-cigarettes in helping smokers quit in Leicester City, UK. It notes that success rates were up to 20% higher using e-cigarettes compared to nicotine replacement therapy alone. A stop smoking service in Leicester City began offering free e-cigarette starter kits in 2014 and has seen consistently high quit rates each year since. Common myths about potential health harms, nicotine addiction, e-cigarettes not reflecting smoker preferences, gateway effects, and lack of evidence are addressed. Key organizations in the UK support e-cigarettes as much safer than smoking and effective for harm reduction.
Vaping and tobacco: six things you need to know about harm reductionClive Bates
1. Smoking has not gone away
2. Technologies to obsolete cigarettes
3. Risks and risk (mis)perceptions
4. The public health mechanism and the pleasure principle
5. The youth vaping epidemic – a harder look
6. Policymaking and perverse consequences
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
This document summarizes a presentation on the effects of alternative nicotine delivery systems like e-cigarettes on cigarette consumption and smoking prevalence. It discusses data showing declines in smoking rates in countries where vaping products are widely available and accepted like the US, UK, and Sweden. Studies suggest vaping helps increase smoking cessation rates at a population level. The rise of Juul products in the US may have accelerated declines in youth smoking rates there in recent years. Countries in Asia have also seen significant drops in cigarette sales as heat-not-burn tobacco and vaping products gain popularity. However, public health attitudes can influence how quickly reduced risk alternatives are adopted.
Dr. Terry F. Pechacek, professor of health management and policy at the School of Public Health at Georgia State University, discusses strategies for tobacco control, including the impact of of e-cigarettes.
This document discusses efforts to develop safer cigarettes through modifying tobacco and reducing tar and toxic compounds. In the 20th century, tobacco companies experimented with adding filters and other additives to cigarettes in attempts to make them less hazardous. One promising attempt involved adding palladium to tobacco, but this "Epic" brand was withheld from the market due to pressure from tobacco control groups and other companies. Later attempts in the 1970s by government and industry to develop "tobacco substitutes" and ultra-low tar cigarettes also failed commercially. Opponents argued safer cigarettes could deter quitting and mask the true risks of smoking. Overall, fully neutralizing the harms of smoking has proved very difficult due to the many toxic compounds produced from
E-Cigarettes a Disruptive Public Health Phenomenon - Professor Antoine FlahaultLindsay Fox
E-cigarettes are a disruptive public health phenomenon that requires consideration of ethics, risks, and the precautionary principle. The precautionary principle calls for caution in the face of uncertainty and cost-effective measures to prevent harm, even without full scientific certainty. While e-cigarettes' risks are uncertain, cigarettes definitively cause death and disease. Lack of certainty on e-cigarettes should not prevent recommending them as part of tobacco control until long-term effects are known, as they may dramatically reduce risks compared to cigarettes.
E-cigarettes were invented in 2003 and entered the US market in 2007. Their use has grown rapidly, with sales exceeding $1 billion in 2013. While e-cigarettes may be less harmful than combustible cigarettes and have helped some smokers quit, their long-term health effects are unclear. Their rise has generated significant debate, as public health experts are concerned they could renormalize smoking or serve as a gateway for youth. The FDA proposed regulating e-cigarettes in 2014 to protect public health, but some argue this may not go far enough to restrict youth access and marketing. Going forward, further research and surveillance are needed to understand e-cigarettes' overall impact on public health.
This document discusses several novel nicotine products that have entered the market, including nicotinis
(martinis with tobacco juice), nicotine lollipops, nicotine wafers, and nicotine water. It raises concerns that
unlike FDA-approved nicotine cessation products, the safety and effectiveness of these novel products is
unknown since they have not undergone necessary clinical trials and FDA approval. The document advises
tobacco users to follow the guidelines of health experts and use proven FDA-approved cessation methods
if wanting to quit.
- The document discusses nicotine testing methods and their use in various contexts like insurance, employment, schools, and research. It also covers nicotine metabolism and the differences between nicotine and its metabolite cotinine.
- The Nano-Check Rapid Nicotine Test is described as an immunoassay that detects cotinine in urine at cutoff levels of 200ng/ml or 500ng/ml to determine tobacco use. It provides results in 5-10 minutes and is intended for professional use.
- The test works by detecting cotinine in a urine sample via monoclonal antibodies on a test strip, with positive or negative results depending on whether or not a test line appears within the timeframe.
Overview of electronic cigarettes including history, components, safety and adverse events, efficacy in smoking cessation, pharmacokinetics and epidemiology. This presentation was originally delivered to 2nd year pharmacy students as part of a two semester class on pharmacology and toxicology.
The electronic cigarette was invented in China in 2004 by pharmacist Hon Lik. It consists of a battery, cartridge containing liquid (often with nicotine), and atomizer. When used, it produces an aerosol that some studies have found contains toxic chemicals and particles, though at lower levels than cigarette smoke. Nicotine in e-cigarettes is highly addictive and can be toxic at low levels, especially for youth. Major tobacco companies have entered the e-cigarette market due to declining cigarette sales. While e-cigarettes may contain fewer toxins than cigarettes, they are not harmless.
This document discusses electronic cigarettes (ECs) and whether they are safer than combustible cigarettes. It summarizes that while ECs may expose users to fewer harmful chemicals than smoking, the long-term safety of ECs is still unknown. Studies have found potentially harmful chemicals in EC vapor, but in much lower amounts than in cigarette smoke. The regulation of ECs is also debated, as stricter rules may discourage innovation but make the products less appealing to youth and non-smokers. The evidence that ECs help smokers quit is also limited and inconclusive. More research is still needed to understand the public health impact of ECs.
Tobacco Harm Reduction by Somchai Bovornkitti* in Crimson Publishers: Telemedicine and e-Health open access journals
Cigarette smoke contain approximately 250 different chemicals known to be harmful to human health. Thousands of harmful chemical substances produce by the combustion of tobacco. The health impacts such as cancer and chronic lung disease are not only associated with smokers but also people who are exposed to secondhand smoke. Tobacco Harm Reduction is a concept to minimize the impacts of tobacco on the individual and on society at large. A key component of this strategy is using alternative source of nicotine as a substitute to tobacco cigarettes. Electronic cigarette and heated tobacco are alternatives that might have potential in reduce harm from smokes. This paper elaborates on available research associated with electronic cigarette and heated tobacco with harm reduction and risk perspective.
https://crimsonpublishers.com/tteh/fulltext/TTEH.000522.php
For more Open access journals in Crimson Publishers
Please click on: https://crimsonpublishers.com/
For more Articles on Telemedicine and e-Health open access journals
please click on link: https://crimsonpublishers.com/tteh/index.php
Please follow the below link for our LinkedIn page
https://www.linkedin.com/company/crimsonpublishers
The document discusses electronic cigarettes (e-cigarettes), how they work, their components, and benefits compared to traditional cigarettes. It works by vaporizing a liquid solution when the user inhales. The vapor produced contains nicotine but none of the toxins in cigarette smoke. E-cigarettes are presented as less harmful and more socially acceptable than traditional cigarettes. The document also provides background information on Mizoram state in India, including its high tobacco consumption rates, and discusses marketing of e-cigarettes.
E-cigarettes were invented in 2003 as a less harmful alternative to traditional cigarettes. They work by heating a liquid that contains nicotine and flavorings to produce an aerosol that is inhaled. While e-cigarettes may be less risky than smoking, they are not completely safe. Their long-term health impacts are still unknown, and some studies have found links between the particles in e-cigarette aerosol and cardiovascular problems. India has banned e-cigarettes due to concerns about rising youth addiction and unknown health risks. Violators of the ban can face imprisonment and fines.
E-cigarettes were invented in 2003 as a less harmful alternative to traditional cigarettes. They work by heating a liquid that contains nicotine and flavorings to produce an aerosol that is inhaled. While e-cigarettes may be less risky than smoking, they are not completely safe. Their long-term health impacts are still unknown, and some studies have found links between the particles in e-cigarette aerosol and cardiovascular problems. India has banned e-cigarettes due to concerns about rising youth addiction and unknown health risks. Violators of the ban can face imprisonment and fines.
This study compared the effects of cigarette smoke, e-cigarette vapor, and pure nicotine on cell viability using HeLa cells. Various concentrations of smoke and vapor condensates collected from a mechanical smoking system were applied to cells for 24 hours. An MTT assay then measured cell viability. Cigarette smoke exposure resulted in lower viability than e-cigarette vapor, but higher than pure nicotine. The results provide insight into the acute toxicity of these substances and whether e-cigarettes may be less harmful than cigarettes.
E-cigarettes provide an alternative to nicotine delivery through vapor rather than smoke. While they may be less harmful than conventional cigarettes, there are still health risks and unknown long-term effects. The document discusses both sides of the debate around e-cigarettes. Some view them as a harm reduction tool that can help smokers quit, while others are concerned they could renormalize smoking behaviors and expose users to carcinogens. Long-term studies are still needed to fully understand the safety profile of e-cigarettes and their impacts on public health.
A public lecture on Electronic Cigarettes delivered by Dr Lynne Dawkins of the Centre for Addictive Behaviours Research, London South Bank University on 14th November 2018.
A recording of the talk can be found here: https://youtu.be/VpetvlAmIaU
Following her successful public lecture on E-Cigarettes in 2013, Dr Dawkins re-visits the subject of e-cigarettes and vaping, drawing on the most recent evidence and updates since 2013. She describes the development in e-cigarette technology and current regulation and then brings the audience up to date with the latest research on usage patterns, smoking cessation and safety issues, addressing some of the common myths held around e-cigarettes and vaping.
India - Economic Times - Consumer Freedom Conclave - 24 Feb 2022Clive Bates
Tobacco harm reduction: the biggest public health win of the 21st Century?
1. Tobacco harm reduction
2. Risk communication
3. Policymaking
4. Cause of opposition
5. Innovation
Effects of alternative nicotine delivery systems on cigarette consumption and...Clive Bates
This document summarizes a presentation on the effects of alternative nicotine delivery systems like e-cigarettes on cigarette consumption and smoking prevalence. It discusses data showing declines in smoking rates in countries where vaping products are widely available and accepted like the US, UK, and Sweden. Studies suggest vaping helps increase smoking cessation rates at a population level. The rise of Juul products in the US may have accelerated declines in youth smoking rates there in recent years. Countries in Asia have also seen significant drops in cigarette sales as heat-not-burn tobacco and vaping products gain popularity. However, public health attitudes can influence how quickly reduced risk alternatives are adopted.
Dr. Terry F. Pechacek, professor of health management and policy at the School of Public Health at Georgia State University, discusses strategies for tobacco control, including the impact of of e-cigarettes.
This document discusses efforts to develop safer cigarettes through modifying tobacco and reducing tar and toxic compounds. In the 20th century, tobacco companies experimented with adding filters and other additives to cigarettes in attempts to make them less hazardous. One promising attempt involved adding palladium to tobacco, but this "Epic" brand was withheld from the market due to pressure from tobacco control groups and other companies. Later attempts in the 1970s by government and industry to develop "tobacco substitutes" and ultra-low tar cigarettes also failed commercially. Opponents argued safer cigarettes could deter quitting and mask the true risks of smoking. Overall, fully neutralizing the harms of smoking has proved very difficult due to the many toxic compounds produced from
E-Cigarettes a Disruptive Public Health Phenomenon - Professor Antoine FlahaultLindsay Fox
E-cigarettes are a disruptive public health phenomenon that requires consideration of ethics, risks, and the precautionary principle. The precautionary principle calls for caution in the face of uncertainty and cost-effective measures to prevent harm, even without full scientific certainty. While e-cigarettes' risks are uncertain, cigarettes definitively cause death and disease. Lack of certainty on e-cigarettes should not prevent recommending them as part of tobacco control until long-term effects are known, as they may dramatically reduce risks compared to cigarettes.
E-cigarettes were invented in 2003 and entered the US market in 2007. Their use has grown rapidly, with sales exceeding $1 billion in 2013. While e-cigarettes may be less harmful than combustible cigarettes and have helped some smokers quit, their long-term health effects are unclear. Their rise has generated significant debate, as public health experts are concerned they could renormalize smoking or serve as a gateway for youth. The FDA proposed regulating e-cigarettes in 2014 to protect public health, but some argue this may not go far enough to restrict youth access and marketing. Going forward, further research and surveillance are needed to understand e-cigarettes' overall impact on public health.
This document discusses several novel nicotine products that have entered the market, including nicotinis
(martinis with tobacco juice), nicotine lollipops, nicotine wafers, and nicotine water. It raises concerns that
unlike FDA-approved nicotine cessation products, the safety and effectiveness of these novel products is
unknown since they have not undergone necessary clinical trials and FDA approval. The document advises
tobacco users to follow the guidelines of health experts and use proven FDA-approved cessation methods
if wanting to quit.
- The document discusses nicotine testing methods and their use in various contexts like insurance, employment, schools, and research. It also covers nicotine metabolism and the differences between nicotine and its metabolite cotinine.
- The Nano-Check Rapid Nicotine Test is described as an immunoassay that detects cotinine in urine at cutoff levels of 200ng/ml or 500ng/ml to determine tobacco use. It provides results in 5-10 minutes and is intended for professional use.
- The test works by detecting cotinine in a urine sample via monoclonal antibodies on a test strip, with positive or negative results depending on whether or not a test line appears within the timeframe.
Overview of electronic cigarettes including history, components, safety and adverse events, efficacy in smoking cessation, pharmacokinetics and epidemiology. This presentation was originally delivered to 2nd year pharmacy students as part of a two semester class on pharmacology and toxicology.
The electronic cigarette was invented in China in 2004 by pharmacist Hon Lik. It consists of a battery, cartridge containing liquid (often with nicotine), and atomizer. When used, it produces an aerosol that some studies have found contains toxic chemicals and particles, though at lower levels than cigarette smoke. Nicotine in e-cigarettes is highly addictive and can be toxic at low levels, especially for youth. Major tobacco companies have entered the e-cigarette market due to declining cigarette sales. While e-cigarettes may contain fewer toxins than cigarettes, they are not harmless.
This document discusses electronic cigarettes (ECs) and whether they are safer than combustible cigarettes. It summarizes that while ECs may expose users to fewer harmful chemicals than smoking, the long-term safety of ECs is still unknown. Studies have found potentially harmful chemicals in EC vapor, but in much lower amounts than in cigarette smoke. The regulation of ECs is also debated, as stricter rules may discourage innovation but make the products less appealing to youth and non-smokers. The evidence that ECs help smokers quit is also limited and inconclusive. More research is still needed to understand the public health impact of ECs.
Tobacco Harm Reduction by Somchai Bovornkitti* in Crimson Publishers: Telemedicine and e-Health open access journals
Cigarette smoke contain approximately 250 different chemicals known to be harmful to human health. Thousands of harmful chemical substances produce by the combustion of tobacco. The health impacts such as cancer and chronic lung disease are not only associated with smokers but also people who are exposed to secondhand smoke. Tobacco Harm Reduction is a concept to minimize the impacts of tobacco on the individual and on society at large. A key component of this strategy is using alternative source of nicotine as a substitute to tobacco cigarettes. Electronic cigarette and heated tobacco are alternatives that might have potential in reduce harm from smokes. This paper elaborates on available research associated with electronic cigarette and heated tobacco with harm reduction and risk perspective.
https://crimsonpublishers.com/tteh/fulltext/TTEH.000522.php
For more Open access journals in Crimson Publishers
Please click on: https://crimsonpublishers.com/
For more Articles on Telemedicine and e-Health open access journals
please click on link: https://crimsonpublishers.com/tteh/index.php
Please follow the below link for our LinkedIn page
https://www.linkedin.com/company/crimsonpublishers
The document discusses electronic cigarettes (e-cigarettes), how they work, their components, and benefits compared to traditional cigarettes. It works by vaporizing a liquid solution when the user inhales. The vapor produced contains nicotine but none of the toxins in cigarette smoke. E-cigarettes are presented as less harmful and more socially acceptable than traditional cigarettes. The document also provides background information on Mizoram state in India, including its high tobacco consumption rates, and discusses marketing of e-cigarettes.
E-cigarettes were invented in 2003 as a less harmful alternative to traditional cigarettes. They work by heating a liquid that contains nicotine and flavorings to produce an aerosol that is inhaled. While e-cigarettes may be less risky than smoking, they are not completely safe. Their long-term health impacts are still unknown, and some studies have found links between the particles in e-cigarette aerosol and cardiovascular problems. India has banned e-cigarettes due to concerns about rising youth addiction and unknown health risks. Violators of the ban can face imprisonment and fines.
E-cigarettes were invented in 2003 as a less harmful alternative to traditional cigarettes. They work by heating a liquid that contains nicotine and flavorings to produce an aerosol that is inhaled. While e-cigarettes may be less risky than smoking, they are not completely safe. Their long-term health impacts are still unknown, and some studies have found links between the particles in e-cigarette aerosol and cardiovascular problems. India has banned e-cigarettes due to concerns about rising youth addiction and unknown health risks. Violators of the ban can face imprisonment and fines.
This study compared the effects of cigarette smoke, e-cigarette vapor, and pure nicotine on cell viability using HeLa cells. Various concentrations of smoke and vapor condensates collected from a mechanical smoking system were applied to cells for 24 hours. An MTT assay then measured cell viability. Cigarette smoke exposure resulted in lower viability than e-cigarette vapor, but higher than pure nicotine. The results provide insight into the acute toxicity of these substances and whether e-cigarettes may be less harmful than cigarettes.
E-cigarettes provide an alternative to nicotine delivery through vapor rather than smoke. While they may be less harmful than conventional cigarettes, there are still health risks and unknown long-term effects. The document discusses both sides of the debate around e-cigarettes. Some view them as a harm reduction tool that can help smokers quit, while others are concerned they could renormalize smoking behaviors and expose users to carcinogens. Long-term studies are still needed to fully understand the safety profile of e-cigarettes and their impacts on public health.
A public lecture on Electronic Cigarettes delivered by Dr Lynne Dawkins of the Centre for Addictive Behaviours Research, London South Bank University on 14th November 2018.
A recording of the talk can be found here: https://youtu.be/VpetvlAmIaU
Following her successful public lecture on E-Cigarettes in 2013, Dr Dawkins re-visits the subject of e-cigarettes and vaping, drawing on the most recent evidence and updates since 2013. She describes the development in e-cigarette technology and current regulation and then brings the audience up to date with the latest research on usage patterns, smoking cessation and safety issues, addressing some of the common myths held around e-cigarettes and vaping.
India - Economic Times - Consumer Freedom Conclave - 24 Feb 2022Clive Bates
Tobacco harm reduction: the biggest public health win of the 21st Century?
1. Tobacco harm reduction
2. Risk communication
3. Policymaking
4. Cause of opposition
5. Innovation
E-cigarettes, California, basic information and legislative and regulatory su...Kath OConnor
Outlining the basics of e-cigarettes in general and in relation to the California economy, legislation and Federal regulation; plain English explanation of vaping fundamentals with references.
E-cig/Vaping fundamentals and CA legislation Aug 2014Kath OConnor
This PDF covers the fundamentals of personal vaporizers/e-cigarettes/ ENDS/PVD and the current California Health and Safety Code. Glossary and links at the end for citation and further information.
Steam instead of smoke - that sounds good at first. But researchers from the \UK warn of the long-term effects of e-cigarettes. Yet they have yet to be explored. We know that so far.
Tobacco Harm Reduction - an introductionClive Bates
This document provides an introduction to tobacco harm reduction and alternative nicotine products such as e-cigarettes. It summarizes statements from public health organizations that find e-cigarettes to be much less harmful than combustible cigarettes. Research shows e-cigarettes help smokers quit at the population level and are effective cessation tools. The document argues for risk-proportionate regulation and taxation of nicotine products to incentivize smokers to switch to less harmful options and further reduce smoking rates.
Similar to E-Cigarettes - How should Public Health respond? - Linda Bauld (20)
Loneliness is an important public health issue, especially for older adults. Thomas Prohaska from Ulster University presented on interventions that can help reduce loneliness in later life from December 5-7, 2018. The presentation discussed what types of programs and activities have been shown to effectively help older adults feel less lonely and socially isolated.
This 3 sentence document provides information about a presentation given at an international loneliness symposium in Belfast from December 5-7, 2018. Theo van Tilburg from Vrije Universiteit Amsterdam presented on the topic of older adult's loneliness in the Netherlands. The symposium was hosted by the Institute of Public Health in Ireland and Ulster University's Bamford Centre for Health and Well Being.
Loneliness in the UK is the topic of the document. The author thanks the funders of her work on loneliness and her collaborators for their contributions and tolerance of her obsession with loneliness. The views expressed are the author's own and should not be attributed to others.
Isolation and loneliness are growing problems in the United States, according to experts James Lubben and Louise McMahon Ahearn. Lubben is a professor emeritus at Boston College and co-investigator for the Boston Roybal Center for Active Lifestyle Interventions, while Ahearn is a professor emeritus at both Boston College and UCLA. They have studied isolation and loneliness in older adults in the U.S.
The MESAS approach to evaluating Scotland's alcohol strategy and minimum unit pricing policy focuses on building a robust evidence base through a portfolio of quantitative and qualitative studies. It aims to determine the policy's impact on alcohol consumption and harms while considering external factors, and to communicate findings in a way that informs the upcoming parliamentary vote without becoming too politicized. The evaluation emphasizes theoretical frameworks, mixed methods, transparency, stakeholder engagement, and maintaining its credibility and independence to ensure its findings can guide the future of the policy.
This document discusses the science of human walking and its benefits. It explores how walking first evolved in the sea over 420 million years ago based on genetic studies of sea creatures. While walking was long thought to have originated on land, many bottom-dwelling sea animals actually walk along the ocean floor. The document also examines the cognitive and health benefits of walking, such as increased creativity and reduced dementia risk, and argues that cities and towns should be designed to make walking easy, accessible, safe, and enjoyable for all.
The document summarizes the role of a physiotherapist in promoting physical activity and falls prevention for older adults. It discusses:
- The physiotherapist's work in assessing mobility and falls risk, and providing rehabilitation, education and support.
- Evidence that strength and balance training can improve independence and reduce falls risk.
- Barriers to physical activity for older adults and the importance of multi-agency partnerships to address this.
- Components of effective strength and balance programs and tips for implementation across settings.
The document provides guidelines for promoting physical activity to improve mental and physical health for those with mental illness. It aims to 1) support staff in promoting physical activity as a therapeutic tool and 2) provide strategies for staff to help service users incorporate physical activity. Examples of successful physical activity programs are provided, as are key messages and resources. Participant feedback underscores the benefits of physical activity in improving mood, confidence, and social engagement for those with mental illness.
1) The document outlines the structure of health and social care in Northern Ireland, including Integrated Care Partnerships which bring together providers to deliver coordinated care.
2) It discusses frailty, including risk factors like falls, incontinence, polypharmacy, and social isolation. Integrated Care Partnerships are working on projects to address frailty like falls prevention programs.
3) Screening tools can help identify frailty and related conditions. Outcomes may include new diagnoses, referrals to services, and medication changes. Patients report improved confidence and mobility from strength and balance programs.
This document discusses cardiac rehabilitation (CR) programs. It provides an overview of CR, including that it is an underutilized treatment for cardiovascular disease. CR aims to improve physical and emotional condition through exercise, education, and behavior modification. Eligible patients include those who have had a heart attack, stents, bypass surgery, heart failure, or stroke. The document outlines the components of a CR program, including exercise training, education sessions, assessments, and a team-based approach. It discusses measuring outcomes like improved physical fitness and reducing risk factors. Finally, it emphasizes the benefits of CR in improving physical function, mental health, and quality of life.
This document summarizes Michael McCorry's PhD research on interventions to reduce sedentary behavior in older adults. It outlines the objectives to systematically review literature on physical activity and behavioral interventions targeting sedentary time in older populations. A search of various databases retrieved over 19,000 records, which were screened according to PRISMA guidelines. 10 studies met the inclusion criteria and were reviewed in detail, finding mostly low quality evidence and small effect sizes of interventions. The conclusions call for improved measurement of sedentary behavior and more developed interventions in early-stage research.
This document discusses physical activity promotion in primary care. It finds that the UK has high rates of physical inactivity compared to other countries. Regular physical activity can significantly reduce the risk of diseases like cardiovascular disease, diabetes, and cancer. However, getting patients more active is challenging for general practitioners due to time constraints, lack of knowledge, and limited local exercise options. The document recommends solutions like educational toolkits, social prescribing programs, and designating practices as health and wellness centers to address these barriers and better promote physical activity.
The document summarizes research estimating the lifetime costs of childhood obesity in Northern Ireland. It finds that the total lifetime financial cost is £2.25 billion (€2.53 billion). This cost could be reduced by 15.7% or £353.2 million with a 5% reduction in childhood BMI. Compared to the Republic of Ireland, lifetime costs per person are higher in Northern Ireland due to differences in healthcare systems and discount rates. The research indicates huge future costs of inaction and significant potential savings from modest reductions in childhood obesity.
This document discusses food marketing to children and outlines some of the key issues and opportunities for policy changes. It notes that food marketing spends millions advertising unhealthy products to children and that exposure to food ads can account for up to 23% of the variance in children's food choices and obesity rates. It also discusses how digital marketing may amplify the effects of television advertising on children. The document argues for stronger regulations and policies to restrict unhealthy food marketing to children, in line with WHO recommendations. It identifies upcoming opportunities for policy changes being considered in the UK and Ireland.
This document summarizes Northern Ireland's approach to tackling childhood obesity. It discusses the health risks and costs of childhood obesity. The keynote speakers will discuss the marketing of food to children, lifetime costs of childhood obesity, and Northern Ireland's obesity policy and strategy. Northern Ireland's "A Fitter Future for All" framework aims to create an environment supporting a healthy lifestyle and diet. It outlines actions to address early childhood, school environments, food production, and empowering healthy choices. Implementation involves various partners leading different outcomes to prevent and reduce obesity.
This document summarizes the health and wellbeing curriculum in Irish primary and post-primary schools. It outlines the 7 areas covered in the primary school curriculum, including Social, Personal and Health Education (SPHE) which focuses on health, hygiene, family structures and care for the environment. Physical Education is required for 1 hour per week. The post-primary curriculum includes wellbeing as a new area of learning and focuses on culture, curriculum, relationships and policy. SPHE is optional in senior cycle, while Physical Education is offered as both a curriculum subject and exam subject. Partnerships have been formed between government departments to promote healthy lifestyle initiatives in and out of schools.
This document outlines the organizational structure and funding of the Active School Flag program. It describes the staff roles and committees that oversee the program. It also details the annual funding received from the Department of Education and Skills between 2015-2018, which has totaled €475,000 and supported two employees, resources, and operating costs. An additional €213,000 grant was received from Healthy Ireland to support program expansion. The budget is administered by the Mayo Education Centre and subject to financial controls and independent auditing.
More from Institute of Public Health in Ireland (20)
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
E-Cigarettes - How should Public Health respond? - Linda Bauld
1. Electronic cigarettes:Electronic cigarettes:
how should public healthhow should public health
respond?respond?
Linda BauldLinda Bauld
With thanks to
Maciej L. Goniewicz,
John Britton, Robert West
& Martin Dockrell
2. BackgroundBackground
In order to consider how and where e-cigarettesIn order to consider how and where e-cigarettes
feature in the current public health landscape,feature in the current public health landscape,
it’s important to take into account recentit’s important to take into account recent
developments indevelopments in tobacco harm reductiontobacco harm reduction
Harm reduction measures are aimed at thoseHarm reduction measures are aimed at those
smokers who, for whatever reason, are not ablesmokers who, for whatever reason, are not able
or willing toor willing to stop using tobaccostop using tobacco oror stop using nicotine.stop using nicotine.
4. NICE & Licensed Nicotine Products
The harm reduction approaches in the NICE guidanceThe harm reduction approaches in the NICE guidance
can involve substituting the nicotine in tobacco withcan involve substituting the nicotine in tobacco with
nicotine from less harmful, nicotine-containing products.nicotine from less harmful, nicotine-containing products.
These include NRT products that are licensed by theThese include NRT products that are licensed by the
MHRA as pharmaceutical treatments for smoking.MHRA as pharmaceutical treatments for smoking.
There are also unregulated products such as electronicThere are also unregulated products such as electronic
cigarettes. The guidance only recommends use of licensedcigarettes. The guidance only recommends use of licensed
products recognising that when electronic cigarettesproducts recognising that when electronic cigarettes
become licensed, they can be recommended for use.become licensed, they can be recommended for use.
Nicotine-containing products might be used eitherNicotine-containing products might be used either
temporarily or indefinitely and as a partial or completetemporarily or indefinitely and as a partial or complete
substitute for tobaccosubstitute for tobacco
5. NICE & Nicotine-containing productsNICE & Nicotine-containing products
The guidance states that:The guidance states that:
There is reason to believe that lifetime use of licensedThere is reason to believe that lifetime use of licensed
nicotine-containing products will be considerably lessnicotine-containing products will be considerably less
harmful than smokingharmful than smoking
There is little direct evidence on the effectiveness, qualityThere is little direct evidence on the effectiveness, quality
and safety of nicotine-containing products that are notand safety of nicotine-containing products that are not
regulated by the MHRA. However, they are expected to beregulated by the MHRA. However, they are expected to be
less harmful than tobacco.less harmful than tobacco.
6. Hon Lik: inventor of the Ruyan (“Hon Lik: inventor of the Ruyan (“resembling smoking”resembling smoking” ))
e-cigarette, marketed 2004e-cigarette, marketed 2004
9. Growth in useGrowth in use
There are now an estimated 2.1 million users in the UKThere are now an estimated 2.1 million users in the UK
In the Republic of Ireland in 2012 the EurobarometerIn the Republic of Ireland in 2012 the Eurobarometer
survey found that 3% of the Irish population had eversurvey found that 3% of the Irish population had ever
tried e-cigarettes and 1% used them regularlytried e-cigarettes and 1% used them regularly
In the UK by 2014 ever use rose by a factor of 1.9 andIn the UK by 2014 ever use rose by a factor of 1.9 and
current use by 1.7. If a similar rise happened in Ireland,current use by 1.7. If a similar rise happened in Ireland,
we can assume 1.7% of the population regularly use ecigswe can assume 1.7% of the population regularly use ecigs
and 5.6% have ever tried themand 5.6% have ever tried them
Amongst smokers in Ireland, we can estimate that aroundAmongst smokers in Ireland, we can estimate that around
1/3 (34%) have tried them but the figure may now be1/3 (34%) have tried them but the figure may now be
higher.higher.
Source: Eurobarometer and personal correspondence with Fenton Howell
10. Stop smoking aids (England)Stop smoking aids (England)
Source: West et al (2014)
www.smokinginengland.info/lateststatistics
20% use NRT from store
25% use e-cig
40% use nothing
11. • nicotine
• propylen glycol
• glycerin
• water
• flavourings
What is in a cartridge ?
12. • The Food and Drug Administration (FDA) has classified PG as an additive
that is “generally recognized as safe” for use in food.
• It is used to absorb extra water
and maintain moisture in certain
medicines, cosmetics, or food
products.
• PG is also used to create
artificial smoke or fog used
in theatrical productions.
• PG is practically odorless
and tasteless.
PropylenPropylenee GlycolGlycol
13. Current e-cigarette use amongCurrent e-cigarette use among
adults in England 2014adults in England 2014
13
ASH/YouGov March April 2014, Sample in England 10,112
14. Nicotine use by never smokersNicotine use by never smokers
and long-term ex-smokersand long-term ex-smokers
Source: West et al, 2014 N=5,272 from Nov 2013
E-cigarette use by never smokers is negligible
16. Survey of children in GB 2013Survey of children in GB 2013
95%
90%
4%
8%
1%
1%
0%
1%
0% 25% 50% 75% 100%
11to15(N=804)16to18(N=624)
I use them often
(more than once a
week)
I use them sometimes
(more than once a
month)
I have tried them once
or twice
I have never used
them
99%
92%
82%
74%
59%
39%
8%
7%
18%
37%
48%
6%
4%
7%4%
5%
0%
25%
50%
75%
100%
Never
smoked
Tried smoking
once
Used to
smoke
Smoke <1 a
week
Smoke 1-6 a
week
Smoke 6+ a
week
Don't know/
Wouldn't say
I use them often
(more than once a
week)
I use them
sometimes (more
than once a month)
I have tried them
once or twice
I have never used
them
Source: ASH, 2014
Frequency of e-cigarette
use amongst 11-18 year olds
who had ever heard of
e-cigs
E-cigarette use by smoking
status, 11-18 year olds
17. E-cigarette/smoking by children: USAE-cigarette/smoking by children: USA
Source: US CDC data from National Youth Tobacco Survey 2011 and 2012. Graph from Bates & Rodu
20. Do e-cigarettes deliver nicotine?
E-cigarettes generate vapor that contains nicotine, but e-cigarettes brands
and models differ in efficacy and consistency of nicotine vaporization.
In e-cigarettes that vaporize nicotine effectively, the amount inhaled from
15 puffs is lower than smoking a conventional cigarette.
21. Toxicants in e-cigarettes?Toxicants in e-cigarettes?
Other than nicotine, whatOther than nicotine, what
else do e-cigarettes deliver?else do e-cigarettes deliver?
A number of studies haveA number of studies have
looked at this, with at least 8looked at this, with at least 8
toxic compounds identifiedtoxic compounds identified
However all of these were atHowever all of these were at
significantly lower levels thansignificantly lower levels than
in conventional cigarettesin conventional cigarettes
22. • Small study conducted by Goniewcz and colleagues involving 20 tobacco cigarette
smokers
• Subjects were provided with electronic cigarettes with cartridges containing nicotine
• Subjects were asked to substitute their regular cigarettes with e-cigarettes for 2 weeks
• Researchers measured nicotine and selected carcinogens in their bodies
Exposure to toxicantsExposure to toxicants
after switchingafter switching
24. What about the vapour?What about the vapour?
Should we be concerned about e-cigaretteShould we be concerned about e-cigarette
vapour in enclosed public places?vapour in enclosed public places?
Lab studies suggest that the vapour containsLab studies suggest that the vapour contains
nicotine and some toxic metals such as cadium,nicotine and some toxic metals such as cadium,
nickel and lead, but levels are much lower thannickel and lead, but levels are much lower than
in second hand smokein second hand smoke
No current evidence of health harms fromNo current evidence of health harms from
occasional exposureoccasional exposure
However the effects of regular exposure overHowever the effects of regular exposure over
many years is unknown.many years is unknown.
25. Cessation: RCTs of E-cigarettesCessation: RCTs of E-cigarettes
• ‘‘Categoria’ 7.2mg nicotine EC vs. 4.8mgCategoria’ 7.2mg nicotine EC vs. 4.8mg
nicotine EC vs. no nicotine ECnicotine EC vs. no nicotine EC
300 smokers (unwilling to quit)300 smokers (unwilling to quit)
1 year abstinence rates: 13%, 9% and 4%1 year abstinence rates: 13%, 9% and 4%
(Caponnetto et al. 2013)(Caponnetto et al. 2013)
• ‘‘Elusion’ 16mg nicotine EC vs. nicotineElusion’ 16mg nicotine EC vs. nicotine
patch vs. no nicotine ECpatch vs. no nicotine EC
657 participants657 participants
6 month abstinence rates: 7.3%, 5.8% and6 month abstinence rates: 7.3%, 5.8% and
4.1%4.1%
(Bullen et al. 2013)(Bullen et al. 2013)
26. Effectiveness in EnglandEffectiveness in England
Source: West et al (2014)
www.smokinginengland.info/lateststatistics
E-cigarette users were more likely
not to be smoking than those using
NRT bought from a store and those
using nothing
**
** Significantly different from both other groups
27. After adjusting for differencesAfter adjusting for differences
between groupsbetween groups
Source: West et al (2014)
www.smokinginengland.info/lateststatistics
The odds of e-cigarette users still
being abstinent were 61% greater
than those using nothing and 63%
greater than those using NRT
28. Success rates of differentSuccess rates of different
methods of quittingmethods of quitting LowestLowest
Nothing or NRT bought from aNothing or NRT bought from a
storestore
HigherHigher
Prescription NRT/medicine or e-Prescription NRT/medicine or e-
cigarette from a store (about 50%cigarette from a store (about 50%
better)better)
HighestHighest
Specialist support from NHSSpecialist support from NHS
Stop-Smoking Service (aboutStop-Smoking Service (about
200% better)200% better)
29. There has been an increase in the
rate of quitting smoking
More smokers are quittingMore smokers are quitting
•Source: West et al, 2014 ENGLAND ONLY Base: All adults
30. Cigarette consumption has decreased
as has overall nicotine use
Fewer people are using nicotineFewer people are using nicotine
•Source: West et al, 2014 ENGLAND ONLY Base: All adults
31. Cigarette smoking prevalenceCigarette smoking prevalence
Source: West et al, 2014 ENGLAND ONLY Base: All adults
Prevalence is declining faster than in
previous years since 2008
32. A licensed product?A licensed product?
NicoventuresNicoventuresVokeVoke inhaled nicotineinhaled nicotine
33. RegulationRegulation
Medicine’s “walledMedicine’s “walled
garden”?garden”?
• ““Safe” and “effective”Safe” and “effective”
• Therapeutic doseTherapeutic dose
• AdvertisingAdvertising
• VAT 5%VAT 5%
EU’s “NicotineEU’s “Nicotine
Jungle”?Jungle”?
• Health warning on packHealth warning on pack
• Concentration capConcentration cap
• No health claimsNo health claims
• Ad banAd ban
• 20% VAT20% VAT
• Declaration of additivesDeclaration of additives
34. Points for discussionPoints for discussion
• In the struggle to reduce preventable mortality, how do weIn the struggle to reduce preventable mortality, how do we
balance the risks?balance the risks?
• What are the ongoing evidence needs and how do we addressWhat are the ongoing evidence needs and how do we address
them?them?
• Do we need to test diverse responses or do we need a “oneDo we need to test diverse responses or do we need a “one
size fits all” international response now?size fits all” international response now?
• How do we manage tobacco industry involvement and whatHow do we manage tobacco industry involvement and what
scope is there to use the Framework Convention on Tobaccoscope is there to use the Framework Convention on Tobacco
Control?Control?
The device uses heat to vaporize a propylene glycol- or glycerin-based liquid solution into a mist, similar to the way a nebulizer or humidifier vaporizes solutions for inhalation.
The device&apos;s components usually include a small liquid reservoir, a heating element, and a power source, normaly a battery
The device uses heat to vaporize a propylene glycol- or glycerin-based liquid solution into a mist, similar to the way a nebulizer or humidifier vaporizes solutions for inhalation.
The device&apos;s components usually include a small liquid reservoir, a heating element, and a power source, normaly a battery
Use amongst 11-18 year-olds
7% had tried e-cigarettes at least once
2% reported using them ‘sometimes’ (more than once a month) or ‘often’ (more than once a week)
28% of those who had ever used e-cigarettes, had used them within the last month
Use by age
16-18 years: 11% had tried e-cigarettes at least once; 8% reported using them sometimes; and 1% using them often
11-15 years: 4% had tried them at least once and 1% reported using them sometimes; none reported more frequent use.
95% 11-15 year-olds and 90% 16-18 year-olds had never used e-cigarettes
So, in our survey of just under 6,000 smokers we found that…A total of…
Therefore, the key finding is the result after we adjust for differences in a range of socio-demog and smoker characteristics. In these adjusted models, we found that…